P
Przepiorka, Donna
H指数:0
被引数:50
个人简介
暂无内容
教育背景
暂无内容
工作经历
暂无内容
荣誉奖项
暂无内容
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
FDA批准摘要: Ivosidenib用于异柠檬酸脱氢酶-1突变的复发或难治性急性髓系白血病
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
CLINICAL CANCER RESEARCH
IF10.2
FDA批准: Blinatumomab
CLINICAL CANCER RESEARCH
IF10.2

